Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Bioavailability of Nilotinib in Healthy Adults Under Fasted Conditions
Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2025
Bioavailability Study of XS003 (Nilotinib)
Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2025
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Handa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Xspray Pharma Signs License Agreement with Handa Therapeutics
Details : Xspray granted Handa a non-exclusive license to certain Xspray patents for the commercialization of Handa’s Phyrago (dasatinib) product in the U.S. and, in the future, selected Asian markets.
Product Name : Phyrago
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 12, 2025
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Handa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Details : Xspray Pharma's lead product XS004 (dasatinib) is being evaluated in the late-stage clinical trial studies for treating patients suffering from chronic myeloid leukemia.
Product Name : Dasynoc
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna
Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
Details : Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.
Product Name : Dasynoc
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dasatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 24, 2023
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sorafenib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Sorafenib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).
Product Name : Dasynoc
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 24, 2023
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : QPS Bioserve India
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dasatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : QPS Bioserve India
Deal Size : Inapplicable
Deal Type : Inapplicable